Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

December 19, 2023

Study Completion Date

December 31, 2024

Conditions

Diabetic FootDiabetic Foot UlcerDiabetic Foot Ulcer Neuropathic

Interventions

BIOLOGICAL

hOMSC200

Human Oral Mucosal Stem Cells

OTHER

Placebo

Animal component-free, defined cryopreservation medium with 5% DMSO

Trial Locations (1)

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors

lead

Cytora Ltd.

INDUSTRY